Anzeige
Mehr »
Login
Montag, 30.03.2020 Börsentäglich über 12.000 News von 622 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Endpoints News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
SoGilead CEO Dan O'Day offers a detailed explanation on remdesivir access - reassuring analysts that Covid-19 data are coming fast
FrAs share buybacks come under scrutiny, what's in store for the biopharma industry?
FrA Singapore VC raises $200M for a new round, but will Covid-19 prevent it from raising the rest?
FrStruggling Unum execs are ready to consider a sale, merger or any deal that comes its way
FrFDA ends CSR pilot, plots new approach for disclosing study reports
FrJim Robinson takes over the reins at Urovant; Carlos Campoy moves to CytomX
FrVBL and its "gene therapy" cancer treatment are back - with a peek at PhIII potential
FrUPDATED: Covid-19 roundup: British PM Johnson tests positive for coronavirus; More companies join hunt for Covid-19 vaccine
FrSanofi turns to an upstart in the mRNA field in latest attempt to quickly squelch a global pandemic
DoPfizer hits the brakes on (most) trial recruitment - but they're circling the wagons around top priorities
DoPfizer, Mylan deal takes a coronavirus hit
DoTakeda antes up $44M for rare disease pact, turning to Oxford spinout's exosome tech
DoEMA offers methodological considerations for trials during Covid-19 pandemic
DoKept on hold at the FDA, Ipsen scraps a key trial and revamps R&D path for its troubled $1B-plus rare disease drug
DoCoupling mRNA with tRNA and new delivery tech, MPM and OrbiMed help birth new $80M biotech into a slowed down world
DoSutroVax lands another $100M+ in upstart quest against Pfizer's blockbuster Prevnar 13
DoCovid-19 roundup: Biopharma industry teams up to spur defensive arsenal to fight pandemic; Regeneron relaxes Eylea payment terms
DoBristol Myers bags its 'blockbuster' FDA OK for ozanimod as a long and winding R&D road finally ends in the marketplace
MiAfter critics lambasted Gilead for grabbing the FDA's special rare drug status on remdesivir, they're giving it back
MiRoche forges deal with San Diego biotech, betting on new antibiotic class
MiOprah day in biotech: Regenacy gets $30M, Abbisko gets $70M, Castle Creek gets $75M
MiCovid-19 roundup: Bristol Myers suspends clinical trials, grounds field team; Vir ushers antibody candidates to human testing
MiIn two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug
MiFDA issues another safety alert related to fecal transplants, as data suggest coronavirus lingers in poop
MiBeiGene scrambles to find new Abraxane supplier as Chinese inspectors order halt on imports, citing Bristol Myers failure